NLM Digital Collections

Search

Search Constraints

Start Over You searched for: Subjects United States Remove constraint Subjects: United States Languages English Remove constraint Languages: English

Search Results

2921. Nucleic acid testing (NAT) for human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV): testing, product disposition, and donor deferral and reentry

2922. FDA categorization of investigational device exemption (IDE) devices to assist the Centers for Medicare and Medicaid Services (CMS) with coverage decisions: guidance for sponsors, clinical investigators, industry, institutional review boards, and Food and Drug Administration staff

2923. Technical considerations for additive manufactured medical devices: guidance for industry and Food and Drug Administration staff

2924. Use of serological tests to reduce the risk of transmission of Trypanosoma cruzi infection in blood and blood components

2925. Software as a medical device (SAMD): clinical evaluation : guidance for industry and Food and Drug Administration staff

2927. Systemic antibacterial and antifungal drugs: susceptibility test interpretive criteria labeling for NDAs and ANDAs

2928. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system

2929. Best practices for communication between IND sponsors and FDA during drug development: guidance for industry and review staff : good review practice

2930. Unique device identification: policy regarding compliance dates for class I and unclassified devices : immediately in effect guidance for industry and Food and Drug Administration staff